Showing results (81-90 of 108) with videos related to
Sort By:
Pageof 11
Cell Chemical Biology|July 11, 2020
Pharmacological Targeting of Vacuolar H<sup>+</sup>-ATPase via Subunit V1G Combats Multidrug-Resistant CancerYuezhou Wang, Lei Zhang, Yanling Wei, et al.Cancer Discovery|October 10, 2019
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast CancerCarlotta Costa, Ye Wang, Amy Ly, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung CancerIbiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.Cell Reports|December 16, 2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient CareDavid P Kodack, Anna F Farago, Anahita Dastur, et al.Cancer Research Communications|December 12, 2022
Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1Richard Kurupi, Konstantinos V Floros, Sheeba Jacob, et al.Nature|February 24, 2022
Effective drug combinations in breast, colon and pancreatic cancer cellsPatricia Jaaks, Elizabeth A Coker, Daniel J Vis, et al.Oncogene|July 21, 2019
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancerSana Raoof, Iain J Mulford, Heidie Frisco-Cabanos, et al.Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.Cell Reports|February 15, 2018
Differential Effector Engagement by Oncogenic KRASTina L Yuan, Arnaud Amzallag, Rachel Bagni, et al.Pageof 11